Skip to Content

GSK PLC GSK Stock Quote

| Rating as of

XLON:GSK

Morningstar‘s Stock Analysis GSK

Valuation
Currency in GBX
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Undervalued GSK Posts Strong Q3, as Zantac Litigation Concerns Appear Overemphasized

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

GSK reported better-than-expected third-quarter results largely driven by strong sales of COVID-19 treatment Xevudy. However, given the likely decline in Xevudy sales over the next year due to the pandemic receding and strong competing oral COVID-19 treatments, we don’t expect any major changes to our GSK fair value estimate based on the solid results.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics GSK

Company Profile GSK

Business Description

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Contact
980 Great West Road
Brentford, Middlesex, TW8 9GS, United Kingdom
T +44 2080475000
Industry Drug Manufacturers - General
Most Recent Earnings Sep 30, 2022
Fiscal Year End Dec 31, 2022
Employees 90,083

Related News GSK